Cryoprecipitate: The Current State of Knowledge

Transfusion Medicine Reviews

Volumn 23, Issue 3, 2009, Pages 177-188

  Callum, Jeannie L ^a   Karkouti, Keyvan ^a   Lin, Yulia ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 8 CRYOPRECIPITATE; CONJUGATED ESTROGEN; DESMOPRESSIN; ERYTHROPOIETIN; FIBRIN GLUE; FIBRINOGEN; FIBRONECTIN; FRESH FROZEN PLASMA; HAEMOCOMPLETTAN; STREPTOKINASE; THROMBOCYTE CONCENTRATE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; AMNION FLUID EMBOLISM; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CRYOPRECIPITATE; DIALYSIS; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; ENVENOMATION; ERYTHROCYTE TRANSFUSION; FIBRINOGEN DEFECT; HEART SURGERY; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOFIBRINOGENEMIA; INFECTION RISK; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREMATURE FETUS MEMBRANE RUPTURE; SNAKEBITE; STROKE; THAWING; TREATMENT INDICATION; UREMIA; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

BLOOD TRANSFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; FIBRINOGEN; GUIDELINES AS TOPIC; HUMANS; KNOWLEDGE; LABORATORY TECHNIQUES AND PROCEDURES;

EID: 67049116011     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2009.03.001     Document Type: Article

References (101)

1. Pool J.G., Hershgold E.J., and Pappenhagen A.R. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature 203 (1964) 312
2. Pool J.G. Preparation and testing of antihemophilic globulin (factor VIII) sources for transfusion therapy in hemophilia. Description of a new sterile concentrate process for blood banks. Scand J Clin Lab Invest 17 (1965) 70-77
3. Bennett E., and Dormandy K. Pool's cryoprecipitate and exhausted plasma in the treatment of von Willebrand's disease and factor-XI deficiency. Lancet 2 (1966) 731-732
4. Barrett K.E., Israëls M.C., and Burn A.M. The effect of cryoprecipitate concentrate in patients with classical hemophilia. Lancet 1 (1967) 191-192
5. Brecher M.E. American Association of Blood Banks Technical Manual. ed 15 (2005), American Association of Blood Banks, Bethesda (Md)
6. Allain J.P. Non-factor VIII related constituents in concentrates. Scand J Haematol 33 (1984) 173-180 (suppl 41)
7. Poon M.C. Cryoprecipitate: Uses and alternatives. Transfus Med Rev 7 (1993) 180-192
8. Romans R: Canadian Blood Services. Personal communication
9. American Association of Blood Banks. Standards for Blood Banks and Transfusion Services. ed 25 (2008), American Association of Blood Banks, Bethesda (Md)
10. Klein H.G., and Anstee D.J. Mollison's Blood Transfusion in Clinical Medicine. ed 11 (2005), Wiley-Blackwell, Malden (Mass)
11. van Gastel C., Sixma J.J., Borst-Eilers E., et al. Preparation and infusion of cryoprecipitate from exercised donors. Br J Haematol 25 (1973) 461-466
12. Kasper C.K., Myhre B.A., McDonald J.D., et al. Determinants of factor VIII recovery in cryoprecipitate. Transfusion 15 (1975) 312-322
13. Kreuz W., Meili E., Peter-Salonen K., et al. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apheresis Sci 32 (2005) 239-244
14. Lundberg G.D. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets: Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA 271 (1994) 777-781
15. Saxena S., Odono V., Francis Jr. R.B., et al. Can storage of thawed cryoprecipitate be extended to more than six hours?. Am J Clin Pathol 94 (1990) 203-206
16. Lovejoy A.E., Reynolds T.C., Visich J.E., et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 108 (2006) 57-62
17. Board P.G., Losowsky M.S., and Miloszewski K.J. Factor XIII: Inherited and acquired deficiency. Blood Rev 7 (1993) 229-242
18. Saba T.M., and Jaffe E. Plasma fibronectin (opsonic glycoprotein): Its synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma are related to reticuloendothelial function. Am J Med 68 (1980) 577-594
19. Reilly J.T., McVerry B.A., and Mackie M.J. Fibronectin in blood products-An in vitro and in vivo study. J Clin Pathol 36 (1983) 1377-1381
20. McVerry B.A., and Machin S.J. Incidence of allo-immunization and allergic reactions to cryoprecipitate in haemophilia. Vox Sang 36 (1979) 77-80
21. George J.N., Pickett E.B., and Heinz R. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood 68 (1986) 307-309
22. Ardoin S.P., Shanahan J.C., and Pisetsky D.S. The role of microparticles in inflammation and thrombosis. Scand J Immunol 66 (2007) 159-165
23. Burman D., Hodson A.K., Wood C.B.S., et al. Acute anaphylaxis, pulmonary oedema, and intravascular haemolysis due to cryoprecipitate. Arch Dis Child 48 (1973) 483-485
24. Canadian Blood Services. Circular of information for the use of human blood and blood components 2005 (2005), Canadian Blood Services, Ottawa (ON)
25. American Association of Blood Banks. Blood Transfusion Therapy: A Physician's Handbook. ed 7 (2002), American Red Cross, Bethesda (Md)
26. Canadian Standards Association. CSA Z902: Blood and blood components (2004), Canadian Standards Association, Mississauga (ON). http://www.wales.nhs.uk/documents/WHC_2005_066.pdf
27. http://hospital.blood.co.uk/library/pdf/mailout_september07.pdf National Blood Service, Bulletin, 27th Sept, 2007
28. http://www.transfusionguidelines.org/docs/pdfs/oig_report.pdf
29. Salter D., and Lloyd A. EU Blood Directive-blood safety and quality regulations 2005. Welsh Health Circ (2005). http://www.wales.nhs.uk/documents/WHC_2005_066.pdf
30. Alport E.C., Callum J.L., Nahirniak S., et al. Cryoprecipitate use in 25 Canadian hospitals: Commonly used outside of published guidelines. Transfusion 48 (2008) 2122-2127
31. Ketchum L., Hess J.R., and Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma 60 (2006) S51-S58 (6 Suppl)
32. Ho A.M., Karmakar M.K., and Dion P.W. Are we giving enough coagulation factors during major trauma resuscitation?. Am J Surg 190 (2005) 479-484
33. Stinger H.K., Spinella P.C., Perkins J.G., et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 64 (2008) S79-S85 (2 Suppl)
34. Cinat M.E., Wallace W.C., Nastanski F., et al. Improved survival following massive transfusion in patients who have undergone trauma. Arch Surg 134 (1999) 964-968
35. Counts R.B., Haisch C., Simon T.L., et al. Hemostasis in massively transfused trauma patients. Ann Surg 190 (1979) 91-99
36. Mannucci P.M., Federici A.B., and Sirchia G. Hemostasis testing during massive blood replacement: A study of 172 cases. Vox Sang 42 (1982) 113-123
37. Ciavarella D., Reed R.L., Counts R.B., et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 67 (1987) 365-368
38. Hewson J.R., Neame P.B., Kumar N., et al. Coagulopathy related to dilution and hypotension during massive transfusion. Crit Care Med 13 (1985) 387-391
39. Phillips T.F., Soulier G., and Wilson R.F. Outcome of massive transfusion exceeding two blood volumes in trauma and emergency surgery. J Trauma 27 (1987) 903-910
40. Horst H.M., Dlugos S., Fath J.J., et al. Coagulopathy and intraoperative blood salvage (IBS). J Trauma 32 (1992) 646-652
41. Faringer P.D., Mullins R.J., Johnson R.L., et al. Blood component supplementation during massive transfusion of AS-1 red cells in trauma patients. J Trauma 34 (1993) 481-485
42. Singbartl K., Innerhofer P., Radvan J., et al. Hemostasis and hemodilution: A quantitative mathematical guide for clinical practice. Anesth Analg 96 (2003) 929-935
43. Hirshberg A., Dugas M., Banez E.I., et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: A computer simulation. J Trauma 54 (2003) 454-463
44. Delgado-Rodriguez M., and Llorca J. Bias. J Epidemiol Community Health 58 (2004) 635-641
45. Horsey P.J. Multiple trauma and massive transfusion. Anaesthesia 52 (1997) 1027-1029
46. O'Shaughnessy D.F., Atterbury C., Bolton Maggs P., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 126 (2004) 11-28
47. Lal A.B., Maruthavanan R., Scott N.B., et al. Aortic valve repair in a patient with congenital afibrinogenemia. Anesth Analg 101 (2005) 1628-1630
48. Rodriguez R.C., Buchanan G.R., and Clanton M.S. Prophylactic cryoprecipitate in congenital afibrinogenemia. Clin Pediatr (Phila) 27 (1988) 543-545
49. Thompson H.W., Touris S., Giambartolomei S., et al. Treatment of congenital afibrinogenemia with cryoprecipitate collected through a plasmapheresis program using dedicated donors. J Clin Apheresis 13 (1998) 143-145
50. Kreuz W., Meili E., Peter-Salonen K., et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apheresis Sci 32 (2005) 247-253
51. Bengtson J.M., VanMarter L.J., Barss V.A., et al. Pregnancy outcome after premature rupture of the membranes at or before 26 weeks' gestation. Obstet Gynecol 73 (1989) 921-927
52. Rotschild A., Ling E.W., Puterman M.L., et al. Neonatal outcome after prolonged preterm rupture of the membranes. Am J Obstet Gynecol 162 (1990) 46-52
53. Quintero R.A., Morales W.J., Allen M., et al. Treatment of iatrogenic previable premature rupture of membranes with intra-amniotic injection of platelets and cryoprecipitate (amniopatch): Preliminary experience. Am J Obstet Gynecol 181 (1999) 744-749
54. Sipurzynski-Budrass S., Macher S., Haeusler M., et al. Successful treatment of premature rupture of membranes after genetic amniocentesis by intra-amniotic injection of platelets and cryoprecipitate (amniopatch): A case report. Vox Sang 91 (2006) 88-90
55. Sciscione A.C., Manley J.S., Pollock M., et al. Intracervical fibrin sealants: A potential treatment for early preterm premature rupture of the membranes. Am J Obstet Gynecol 184 (2001) 368-373
56. French C.J., Bellomo R., and Angus P. Cryoprecipitate for the correction of coagulopathy associated with liver disease. Anaesth Intensive Care 31 (2003) 357-361
57. Nugent D.J. Prophylaxis in rare coagulation disorders-Factor XIII deficiency. Thromb Res 118 (2006) S23-S28 (Suppl 1)
58. Rodeghiero F., Castaman G., Meyer D., et al. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 62 (1992) 193-199
59. Perkins H.A. Correction of the hemostatic defects in von Willebrand's disease. Blood 30 (1967) 375-380
60. Blatt P.M., Brinkhous K.M., Culp H.R., et al. Anti-hemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA 236 (1976) 2770-2772
61. Califf R.M., Topol E.J., George B.S., et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in the treatment of acute myocardial infarction. Am J Med 85 (1988) 353-359
62. Verstraete M., Bernard R., Bory M., et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Lancet 1 (1985) 842-847
63. Sane D.C., Califf R.M., Topol E.J., et al. Bleeding during thrombolytic therapy for acute myocardial infarction: Mechanisms and management. Ann Intern Med 111 (1989) 1010-1022
64. Rao A.K., Pratt C., Berke A., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11 (1988) 1-11
65. Lupinetti F.M., Stoney W.S., Alford Jr. W.C., et al. Cryoprecipitate-topical thrombin glue. Initial experience in patients undergoing cardiac operations. J Thorac Cardiovasc Surg 90 (1985) 502-505
66. Carless P.A., Anthony D.M., and Henry D.A. Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br J Surg 89 (2002) 695-703
67. Carless P.A., Henry D.A., and Anthony D.M. Fibrin sealant use for minimising peri-operative allogeneic blood transfusion. Cochrane Database Syst Rev 2 (2003) CD004171
68. Figueras J., Llado L., Miro M., et al. Application of fibrin glue sealant after hepatectomy does not seem justified: Results of a randomized study in 300 patients. Ann Surg 245 (2007) 536-542
69. Noris M., and Remuzzi G. Uremic bleeding: Closing the circle after 30 years of controversies?. Blood 94 (1999) 2569-2574
70. Livio M., Gotti E., Marchesi D., et al. Uraemic bleeding: Role of anaemia and beneficial effect of red blood cell transfusions. Lancet 2 (1982) 1013-1015
71. Janson P.A., Jubelirer S.J., Weinstein M.J., et al. Treatment of bleeding tendency in uremia with cryoprecipitate. N Engl J Med 303 (1980) 1318-1322
72. Triulzi D.J., and Blumberg N. Variability in response to cryoprecipitate treatment for hemostatic defects in uremia. Yale J Biol Med 63 (1990) 1-7
73. Gilbert W.M., and Danielsen B. Amniotic fluid embolism: Decreased mortality in a population-based study. Obstet Gynecol 93 (1999) 973-977
74. Tuffnell D.J. Amniotic fluid embolism. Curr Opin Obstet Gynecol 15 (2003) 119-122
75. Rodgers G.P., and Heymach G.J. Cryoprecipitate therapy in amniotic fluid embolization. Am J Med 76 (1984) 916-920
76. Rodgers G.P., and Heymach G.J. Amniotic fluid embolism. JAMA 256 (1986) 1892-1893
77. Boyer L.V., Seifert S.A., Clark R.F., et al. Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med 159 (1999) 706-710
78. Robinson R.F., Baker R.S., Martin S., et al. Use of "Near Middle East Antivenom" to treat African bush viper envenomation. Vet Hum Toxicol 46 (2004) 264-265
79. Weis J.R., Whatley R.E., Glenn J.L., et al. Prolonged hypofibrinogenemia and protein C activation after envenoming by Echis carinatus sochureki. Am J Trop Med Hyg 44 (1991) 452-460
80. Ferguson L.A., Morling A., Moraes C., et al. Investigation of coagulopathy in three cases of tiger snake (Notechis ater occidentalis) envenomation. Pathology 34 (2002) 157-161
81. McNally T., Conway G.S., Jackson L., et al. Accidental envenoming by a Gaboon viper (Bitis gabonica): The haemostatic disturbances observed and investigation of in vitro haemostatic properties of whole venom. Trans R Soc Trop Med Hyg 87 (1993) 66-70
82. Kornalik F., and Vorlová Z. Non-specific therapy of a hemorrhagic diathesis after a bite by a young Bothrops asper (barba amarilla): A case report. Toxicon 28 (1990) 1497-1501
83. Saba T.M., Blumenstock F.A., Shah D.M., et al. Reversal of fibronectin and opsonic deficiency in patients: A controlled study. Ann Surg 199 (1984) 87-96
84. Kuusela P. Fibronectin binds to Staphylococcus aureus. Nature 276 (1978) 718-720
85. Scovill W.A., Saba T.M., Kaplan J.E., et al. Disturbances in circulating opsonic activity in man after operative and blunt trauma. J Surg Res 22 (1977) 709-716
86. Scovill W.A., Saba T.M., Kaplan J.E., et al. Deficits in reticuloendothelial humoral control mechanisms in patients after trauma. J Trauma 16 (1976) 898-904
87. Stainsby D., MacLennan S., Thomas D., et al. Guidelines on the management of massive blood loss. Br J Haematol 135 (2006) 634-641
88. Droubatchevskaia N., Wong M.P., Chipperfield K.M., et al. Guidelines for cryoprecipitate transfusion. BC Med J 49 (2007) 441-445
89. Hedges S.J., Dehoney S.B., Hooper J.S., et al. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract 3 (2007) 138-152
90. Canadian Society for Transfusion Medicine. Canadian Standards for Transfusion Medicine (version 2) (2007), Canadian Society for Transfusion Medicine, Ottawa (ON)
91. Council of Europe. Guide to the preparation, use an quality assurance of blood components. ed 12 (2006), Council of Europe Publishing, Strasbourg
92. Hensley M.J. Use and misuse of cryoprecipitate (letter). N Engl J Med 292 (1975) 1299
93. Schofield W.N., Rubin G.L., and Dean M.G. Appropriateness of platelet, fresh frozen plasma and cryoprecipitate transfusion in New South Wales public hospitals. Med J Aust 178 (2003) 117-121
94. Pantanowitz L., Kruskall M.S., and Uhl L. Cryoprecipitate: Patterns of use. Am J Clin Pathol 119 (2003) 874-881
95. Robillard P., Nawej K.I., and Jochem K. The Quebec hemovigilance system: Description and results from the first two years. Transfus Apheresis Sci 31 (2004) 111-122
96. McVerry B.A., and Machin S.J. Incidence of allo-immunization and allergic reactions to cryoprecipitate in haemophilia. Vox Sang 36 (1979) 77-80
97. Reese E.P., McCullough J.J., and Craddock P.R. An adverse pulmonary reaction to cryoprecipitate in a haemophiliac. Transfusion 15 (1975) 583-588
98. Musa M.O., Al-Fair F., Al-Mohareb F., et al. Cryoprecipitate-induced mesenteric vein thrombosis during l-asparaginase therapy for acute lymphocytic leukemia. Leuk Lymph 40 (2001) 429-431
99. Payne J.H., and Vora A.J. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 138 (2007) 430-445
100. Aygoren-Pursun E., Martinez Saguer I., Rusicke E., et al. Retrochorionic hematoma in congenital afibrinogenemia: Resolution with fibrinogen concentrate infusions. Am J Hematol 82 (2007) 317-320
101. Yasunaga H. Risk of authoritarianism: Fibrinogen-transmitted hepatitis C in Japan. Lancet 370 (2007) 2063-2067